On November 10, Charles River Laboratories rose 5.04% in Regular Trading, trading at $354.51 per share, with turnover of $84.50 million.
The move followed the company’s announcement that it agreed to acquire Frontage’s bioanalysis and drug metabolism and pharmacokinetics businesses in Exton, Pennsylvania for about $470 million in cash.
The transaction is tied to a broader privatization and delisting of Frontage by a consortium including Charles River Laboratories, Tigermed, and Frontage’s chairman, after which the targeted bioanalysis and DMPK assets are expected to be reorganized and fully taken over by Charles River Laboratories. The deal points to continued portfolio expansion after management previously said it had capacity and interest to pursue acquisitions, while also adding capabilities in services already central to its Discovery and Safety Assessment operations.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments